Order byBest matchMost fresh

Novo Nordisk slashes price of Ozempic

Digest more
GoodRx teams up with Novo Nordisk to make weight loss drugs more affordable
“Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” Wendy Barnes, President and Chief Executive Officer of GoodRx, said in a news release...

Continue reading

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients
Canada approves Ozempic to cut risk of kidney failure, heart-related deaths
Canada has approved Novo Nordisk's (NOVOb.CO) diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of kidney failure and heart-related deaths in type-2 diabetes patie...

Continue reading

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Novo Nordisk halves Ozempic price in US
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
“At the ESC congress, we are presenting new data substantiating the unique range of benefits semaglutide has on people with heart and kidney disease, as demonstrated in both clinical trials and in the...

Continue reading

US cash-paying customers can now get Ozempic for half price
US patients can now get Ozempic for half price if they can pay cash

Novo Nordisk slashes price of Ozempic to $499 for cash-paying, uninsured patients

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.

GoodRx offers coupons for reduced prescription drug prices at retail pharmacies. The company says patients will be able to use GoodRx to self-pay for both Ozempic and Wegovy at the $499-per-month price at 70,000 U.S. retail pharmacies.
Fierce Pharma3h

Novo Nordisk, under new CEO Doustdar, freezes hiring in non-critical business areas

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar Mike Doustdar, the company isn't making a point to rapidly add staffers.
REVOLT on MSN23h

Ozempic reportedly faces $2 billion in lawsuits over severe side effects

Over 1,800 lawsuits claim Ozempic caused stomach paralysis, vision loss, and more. Read what’s next in the legal fight.

Gynaecologist explains little-known side effects as women detail their experiences of 'Ozempic vulva'

Some women are complaining of 'Ozempic vulva' and GLP-1 medications can causes changes to women's private parts.
Feedback